Financings in Brief: Sunrise Technologies
This article was originally published in The Gray Sheet
Sunrise Technologies: Closes $5.9 mil. private placement of convertible notes and warrants. Funds will be used to complete the final clinical development phase of the LTK laser thermal keratoplasty corneal shaping system for treatment of hyperopia, and for continued trials for treatment of presbyopia. The financing is anticipated to provide sufficient funding "well into 1999," and filing by that time of a premarket approval application for hyperopia with FDA, the firm says. The offering includes 12% "payment-in-kind" convertible notes, maturing in January 2001. Investors receive one warrant for every $5 worth of notes. The warrants expire in five years and have an exercise price of $3 per share, which is also the conversion price on the notes...
You may also be interested in...
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.